<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493973</url>
  </required_header>
  <id_info>
    <org_study_id>FA_BBK_8</org_study_id>
    <nct_id>NCT01493973</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Epoetin Alfa in Friedreich Ataxia</brief_title>
  <acronym>FRIEMAX</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Clinical Trial to Test the Efficacy of Epoetin Alfa on Physical Performance of Friedreich Ataxia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Friedreich's Ataxia Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Associazione Italiana per la lotta alle Sindromi Atassiche (AISA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Friedreich's ataxia (FRDA) is a rare genetic disorder characterised by severe neurological
      disability and cardiomyopathy. Friedreich's ataxia is the consequence of frataxin deficiency.
      Although several drugs have been proposed, there is no available treatment. Four trials
      recently demonstrated that erythropoietin can increase the intracellular levels of frataxin.
      The present project is aimed at testing a long term therapeutic approach using
      erythropoietin, which is an already available and commercialised drug. The study will test
      the effect of erythropoietin on exercise capacity, which is reduced in patients with FRDA.
      Additional objectives of the study will be the drug's safety and tolerability, and its effect
      on frataxin, blood vessel reactivity, heart functional indexes, and disease progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Friedreich's ataxia (FA) is an autosomal recessive ataxia caused by a trinucleotide GAA
      expansion in the first intron of the FXN gene. The gene encodes for a 210aa mitochondrial
      protein called frataxin, whose mRNA and protein levels are severely reduced in FA. It has
      been suggested that frataxin is involved in iron-sulphur cluster and heme biogenesis, iron
      binding/storage, and chaperone activity. Clinically, the age of onset is generally around
      puberty and, as the disease progresses, there is increasing ataxia of the limbs, and
      eventually most patients are wheelchair bound by the twenties. Cardiomyopathy with myocardial
      hypertrophy occurs very often and is the predominant cause of death. Type II diabetes,
      scoliosis, foot deformities, optic atrophy, and deafness are other relatively frequent
      symptoms.

      Erythropoietin (EPO) is a glycoprotein that acts as a main regulator for erythropoiesis.
      Evidence suggests that both EPO and its receptor are expressed in the nervous tissue, and
      neuroprotective effects have been shown in animal models of cerebral ischemic damage. EPO
      increases frataxin levels in cultured human lymphocytes from FRDA patients. However, frataxin
      protein increase is not preceded by mRNA increase, suggesting that a post-transcriptional
      mechanism is involved. To date, four phase II clinical trials have been published regarding
      the use of EPO in FRDA patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak oxygen uptake (VO2 max) at the cardiopulmonary exercise test (CPET)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Patients will undergo a complete CPET as described in the methods section. CPET will be performed at baseline (Visit 2), at 24 weeks (Visit 5), and at 48 weeks (Visit 7).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome variables at the CPET (anaerobic threshold, ventilatory efficiency, exercise duration, and power output).</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frataxin levels in peripheral blood mononuclear cells (PBMCs).</measure>
    <time_frame>all timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>24, and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular reactivity</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Vascular reactivity will be measured by the Flow-Mediated Dilation technique (FMD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological progression</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Neurological progression will be measured with the Scale for the Assessment and Rating of Ataxia (SARA), and with the 9 hole pegboard test (9-HPT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Quality of life will be assessed with the EQ-5D, ADL, and IADL scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>all visits</time_frame>
    <description>Safety and tolerability will be assessed by recording all serious and non serious adverse events at all visits of the trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Epoetin alfa 1200 IU/Kg s.c. every 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1200 IU/Kg s.c. every 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
    <description>Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks</description>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <other_name>EPREX 40000 IU</other_name>
    <other_name>EPREX 10000 IU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Molecular diagnosis of Friedreich Ataxia

          -  Age ≥12 years

          -  Body weight ≥30, ≤90 Kg

          -  SARA score ≤30

          -  Patient able to read and sign the informed consent

          -  Patients able to perform a cardiopulmonary test

        Exclusion Criteria:

          -  Treatment with Erythropoietin in the previous 12 months

          -  Treatment with Idebenone

          -  Contraindications to CPET: cardiac valve disease, ischemic cardiomyopathy, atrial
             fibrillation, asthma, chronic obstructive pulmonary disease, other arrhythmias judged
             as not compatible with exercise.

          -  Any Cardiac and/or Hepatic and/or Renal disease judged as clinically relevant by the
             investigator

          -  Any clinically relevant ECG abnormalities that may interfere with the study

          -  Any abnormal and clinically relevant laboratory exams at screening visit that may
             interfere with the trial

          -  Anemia with Hemoglobin &lt;10 g/dL

          -  Positive history for venous and/or arterial thrombosis

          -  Drug-resistant arterial hypertension

          -  Positive history for drug-resistant epilepsy

          -  Patients in treatment with not allowed study drugs (starting from 3 months prior to
             screening)

          -  Any acute/chronic disease that might interfere with the clinical trial, as judged by
             the investigator

          -  Hypersensitivity to Epoetin alfa or any other component of the study drug

          -  Patients not able to comply to the study

          -  For female patients (Sexually not active, hysterectomized, sterilized, menopause
             patients are excluded from the following criteria): pregnancy and/or breastfeeding
             and/or inadequate contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Saccà, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Federico II, Naples Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Università di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università la Sapienza, Neurologia C</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Neurologiche</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.neurologia.unina.it</url>
    <description>Clinical trials site</description>
  </link>
  <link>
    <url>http://www.unina.it</url>
    <description>University Federico II, Naples Italy</description>
  </link>
  <link>
    <url>http://www.curefa.org</url>
    <description>Friedreich Ataxia Research Alliance</description>
  </link>
  <link>
    <url>http://www.atassia.it</url>
    <description>Associazione Italiana per la lotta alle Sindromi Atassiche</description>
  </link>
  <reference>
    <citation>Saccà F, Piro R, De Michele G, Acquaviva F, Antenora A, Carlomagno G, Cocozza S, Denaro A, Guacci A, Marsili A, Perrotta G, Puorro G, Cittadini A, Filla A. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Mov Disord. 2011 Mar;26(4):739-42. doi: 10.1002/mds.23435. Epub 2010 Nov 10.</citation>
    <PMID>21506154</PMID>
  </reference>
  <reference>
    <citation>Acquaviva F, Castaldo I, Filla A, Giacchetti M, Marmolino D, Monticelli A, Pinelli M, Saccà F, Cocozza S. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum. 2008;7(3):360-5. doi: 10.1007/s12311-008-0036-x.</citation>
    <PMID>18581197</PMID>
  </reference>
  <reference>
    <citation>Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, Goldenberg H, Poewe W. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord. 2008 Oct 15;23(13):1940-4. doi: 10.1002/mds.22294.</citation>
    <PMID>18759345</PMID>
  </reference>
  <reference>
    <citation>Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Mojdehkar B. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol. 2007 Nov;62(5):521-4.</citation>
    <PMID>17702040</PMID>
  </reference>
  <reference>
    <citation>Sturm B, Stupphann D, Kaun C, Boesch S, Schranzhofer M, Wojta J, Goldenberg H, Scheiber-Mojdehkar B. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest. 2005 Nov;35(11):711-7.</citation>
    <PMID>16269021</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Alessandro Filla</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>EPO</keyword>
  <keyword>Friedreich</keyword>
  <keyword>Ataxia</keyword>
  <keyword>Epoetin alfa</keyword>
  <keyword>VO2 max</keyword>
  <keyword>SARA</keyword>
  <keyword>EQ-5D</keyword>
  <keyword>frataxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

